{"id":102142,"date":"2020-02-10T07:03:49","date_gmt":"2020-02-10T15:03:49","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/02\/scientists-in-amsterdam-destroyed-breast-cancer-tumors-in-11-days-without-chemo"},"modified":"2020-02-10T07:03:49","modified_gmt":"2020-02-10T15:03:49","slug":"scientists-in-amsterdam-destroyed-breast-cancer-tumors-in-11-days-without-chemo","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/02\/scientists-in-amsterdam-destroyed-breast-cancer-tumors-in-11-days-without-chemo","title":{"rendered":"Scientists in Amsterdam Destroyed Breast Cancer Tumors in 11 Days Without Chemo"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/scientists-in-amsterdam-destroyed-breast-cancer-tumors-in-11-days-without-chemo.jpg\"><\/a><\/p>\n<p>HER2-positive breast cancer is a type of aggressive cancer marked by uncontrolled production of breast cells. About 20% of women and men diagnosed with breast cancer have HER2-positive cancer, specifically.<\/p>\n<p>Currently, oncologists treat HER2-positive breast cancer patients with surgery, radiation, chemotherapy, or targeted treatments like Herceptin (trastuzumab), Kadcyla (Ado-trastuzumab-emtansine), Perjeta (Pertuzumab), and Tykerb (Lapatinib).<\/p>\n<p>These targeted treatments work by interfering with the protein that signals breast cell production, and they\u2019re often used in conjunction with chemotherapy, which undoubtedly, can be a very arduous treatment process.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HER2-positive breast cancer is a type of aggressive cancer marked by uncontrolled production of breast cells. About 20% of women and men diagnosed with breast cancer have HER2-positive cancer, specifically. Currently, oncologists treat HER2-positive breast cancer patients with surgery, radiation, chemotherapy, or targeted treatments like Herceptin (trastuzumab), Kadcyla (Ado-trastuzumab-emtansine), Perjeta (Pertuzumab), and Tykerb (Lapatinib). These [\u2026]<\/p>\n","protected":false},"author":525,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-102142","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/102142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/525"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=102142"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/102142\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=102142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=102142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=102142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}